PharmaBlock Sciences 2026 Interim Report: Net Profit Attributable to Parent at 99.4449 Million Yuan, Up 37.17% Year-on-Year

Earnings
โดย Jiemian·Read original
Summary · why it matters

PharmaBlock Sciences released its 2026 interim report, with net profit attributable to the parent company at 99.4449 million yuan, up 37.17% from the same period last year. The company's total operating revenue was 1.059 billion yuan, a year-on-year increase of 15.19%, marking two consecutive years of growth. Net cash inflow from operating activities was 192 million yuan, down 58.80% year-on-year. The company's latest asset-liability ratio is 15.19%, gross margin is 32.49%, ROE is 2.18%, and diluted earnings per share is 0.43 yuan.

Impact on stocks 1

Others▲ · 1 stocks
© 2026 MarketDXNews